A Phase 2/3 interventional study of Acetazolamide and Dexamethasone in Neurocysticercosis, sponsored by Universidad Peruana Cayetano Heredia. Terminated at 1 site in Peru. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by Universidad Peruana Cayetano Heredia · Phase 2/3, Interventional, and Treatment
Three-arm open, randomized comparative study of acetazolamide, dexamethasone, or no additional treatment to evaluate decrease in peri-calcification edema in neurocysticercosis
This study will evaluate 24 patients with calcified NCC and edema in three treatment arms to compare the reduction in edema volume
21 studies on the registry are indexed under Neurocysticercosis; 5 are open to participants now.
This study's enrollment of 4 is below the median of 107 across 13 interventional studies indexed under Neurocysticercosis.
Browse Neurocysticercosis studies →Universidad Peruana Cayetano Heredia is the lead sponsor of 49 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
750 mg acetazolamide p.o. divided in three dily doses, for 10 days
Drug: Acetazolamide
8 mg p.o. divided in three daily daily doses, for 2 days followed by gradual tapering
Drug: Dexamethasone
No additional treatment
As described above
As described above
Decrease in Volume of Perilesional Edema Between Baseline and Day 4
MRI extension of edema
Time frame: Baseline to Day 4
Decrease in Volume of Perilesional Edema Between Baseline and Day 8
MRI extension of edema
Time frame: Baseline to Day 8
Decrease in Volume of Perilesional Edema Between Baseline and Day 30
MRI extension of edema
Time frame: Baseline to Day 30
Plan to share: No — As a concrete product, the clinical trial should provide base data to implement an affordable therapy for edema-related seizures. The data produced was going to be published in a peer reviewed journal; nevertheless, the study was prematurely terminated due to low recruitment.
No publications or documents are linked to this record.
Ran from Dec 2015 to primary completion in Dec 2018, 36 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetazolamide · Dexamethasone
Universidad Peruana Cayetano Heredia